Terms: = Breast cancer AND IL2, IL-2, 3558, ENSG00000109471, P60568
644 results:
1. Immune Checkpoint Inhibitor Use During Pregnancy and Outcomes in Pregnant Individuals and Newborns.
Gougis P; Hamy AS; Jochum F; Bihan K; Carbonnel M; Salem JE; Dumas E; Kabirian R; Grandal B; Barraud S; Coussy F; Hotton J; Savarino R; Marabelle A; Cadranel J; Spano JP; Laas E; Reyal F; Abbar B
JAMA Netw Open; 2024 Apr; 7(4):e245625. PubMed ID: 38630478
[TBL] [Abstract] [Full Text] [Related]
2. Role of beta-(1→3)(1→6)-D-glucan derived from yeast on natural killer (NK) cells and breast cancer cell lines in 2D and 3D cultures.
Boulifa A; Raftery MJ; Franzén AS; Radecke C; Stintzing S; Blohmer JU; Pecher G
BMC Cancer; 2024 Mar; 24(1):339. PubMed ID: 38486205
[TBL] [Abstract] [Full Text] [Related]
3. Building a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell Therapy.
Maia A; Tarannum M; Lérias JR; Piccinelli S; Borrego LM; Maeurer M; Romee R; Castillo-Martin M
Cells; 2024 Mar; 13(5):. PubMed ID: 38474415
[TBL] [Abstract] [Full Text] [Related]
4. Cytokine Plasma Levels in breast cancer Patients, Before and After Surgery.
Kontomanolis E; Tsigalou C; Mitrakas A; Gkegka AG; Efraimidou E; Karamanidis D; Nikoletos K; Panagiotis T; Nikoletos N; Giatromanolaki A; Koukourakis MI
J Interferon Cytokine Res; 2024 Mar; 44(3):135-142. PubMed ID: 38386538
[TBL] [Abstract] [Full Text] [Related]
5.
Li F; Wu Y; Shi Y; Liu X; Xie Y; Liu S
Acta Biochim Biophys Sin (Shanghai); 2024 Mar; 56(3):462-473. PubMed ID: 38379418
[TBL] [Abstract] [Full Text] [Related]
6. Cytotoxicity of fourth-generation anti-Trop2 CAR-T cells against breast cancer.
Somboonpatarakun C; Phanthaphol N; Suwanchiwasiri K; Ramwarungkura B; Yuti P; Poungvarin N; Thuwajit P; Junking M; Yenchitsomanus PT
Int Immunopharmacol; 2024 Mar; 129():111631. PubMed ID: 38359664
[TBL] [Abstract] [Full Text] [Related]
7. Low glucose availability potentiates the effects of metformin on model T cell activation and exhaustion markers
Repas J; Peternel L; Sourij H; Pavlin M
Front Endocrinol (Lausanne); 2023; 14():1216193. PubMed ID: 38116319
[TBL] [Abstract] [Full Text] [Related]
8. Dual silencing of tumor-intrinsic VISTA and CTLA-4 stimulates T-cell mediated immune responses and inhibits MCF7 breast cancer development.
Hosseinkhani N; Hemmat N; Baghbani E; Baghbanzadeh A; Kazemi T; Mokhtarzadeh A; Jafarlou M; Amin Doustvandi M; Baradaran B
Gene; 2024 Feb; 896():148043. PubMed ID: 38042220
[TBL] [Abstract] [Full Text] [Related]
9. cancer-related fatigue: Towards a more targeted approach based on classification by biomarkers and psychological factors.
Schmidt ME; Maurer T; Behrens S; Seibold P; Obi N; Chang-Claude J; Steindorf K
Int J Cancer; 2024 Mar; 154(6):1011-1018. PubMed ID: 37950650
[TBL] [Abstract] [Full Text] [Related]
10. Treatments During Pregnancy Targeting ERBB2 and Outcomes of Pregnant Individuals and Newborns.
Gougis P; Grandal B; Jochum F; Bihan K; Coussy F; Barraud S; Asselain B; Dumas E; Sebbag C; Hotton J; Spaggiari E; Pierga JY; Savarino R; Laas E; Spano JP; Reyal F; Hamy AS
JAMA Netw Open; 2023 Oct; 6(10):e2339934. PubMed ID: 37883083
[TBL] [Abstract] [Full Text] [Related]
11. Tumor-Targeted Delivery of il-2 by Fusing with a pH Low Insertion Peptide for Antitumor Immunotherapy.
Chu T; Cao B; Wang P; Li B; Ren J; Nie G; Wei J; Li S
Bioconjug Chem; 2023 Oct; 34(10):1894-1901. PubMed ID: 37787935
[TBL] [Abstract] [Full Text] [Related]
12. Tumor-infiltrating lymphocyte transfusion in a patient with treatment refractory triple negative breast cancer.
Jacover A; Zarbiv Y; Tal KH; Klein S; Breuer S; Durst R; Avni B; Grisariu S; Stepensky P; Lotem M; Maimon O; Yablonski-Peretz T
Cancer Rep (Hoboken); 2023 Dec; 6(12):e1894. PubMed ID: 37750497
[TBL] [Abstract] [Full Text] [Related]
13. Nanoadjuvants Produced by Advanced Nanochelating Technology in the Inactivated-Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine Formulation: Preliminary Results on Cytokines and IgG Responses.
Kalanaky S; Fakharzadeh S; Karimi P; Hafizi M; Jamaati H; Hassanzadeh SM; Khorasani A; Mahdavi M; Nazaran MH
Viral Immunol; 2023; 36(6):409-423. PubMed ID: 37506342
[TBL] [Abstract] [Full Text] [Related]
14. PTPRC promoted CD8+ T cell mediated tumor immunity and drug sensitivity in breast cancer: based on pan-cancer analysis and artificial intelligence modeling of immunogenic cell death-based drug sensitivity stratification.
Li P; Wang W; Wang S; Cao G; Pan T; Huang Y; Wan H; Zhang W; Huang Y; Jin H; Wang Z
Front Immunol; 2023; 14():1145481. PubMed ID: 37388747
[TBL] [Abstract] [Full Text] [Related]
15. CD25high Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative breast cancer.
Fattori S; Le Roy A; Houacine J; Robert L; Abes R; Gorvel L; Granjeaud S; Rouvière MS; Ben Amara A; Boucherit N; Tarpin C; Pakradouni J; Charafe-Jauffret E; Houvenaeghel G; Lambaudie E; Bertucci F; Rochigneux P; Gonçalves A; Foussat A; Chrétien AS; Olive D
Cancer Res; 2023 Sep; 83(18):3026-3044. PubMed ID: 37379438
[TBL] [Abstract] [Full Text] [Related]
16. circ-0000512 inhibits PD-L1 ubiquitination through sponging miR-622/CMTM6 axis to promote triple-negative breast cancer and immune escape.
Dong LF; Chen FF; Fan YF; Zhang K; Chen HH
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37349124
[TBL] [Abstract] [Full Text] [Related]
17. Components and effectiveness of patient navigation programmes to increase participation to breast, cervical and colorectal cancer screening: A systematic review.
Mosquera I; Todd A; Balaj M; Zhang L; Benitez Majano S; Mensah K; Eikemo TA; Basu P; Carvalho AL
Cancer Med; 2023 Jul; 12(13):14584-14611. PubMed ID: 37245225
[TBL] [Abstract] [Full Text] [Related]
18. Amygdalin-folic acid-nanoparticles inhibit the proliferation of breast cancer and enhance the effect of radiotherapy through the modulation of tumor-promoting factors/ immunosuppressive modulators in vitro.
Askar MA; El-Sayyad GS; Guida MS; Khalifa E; Shabana ES; Abdelrahman IY
BMC Complement Med Ther; 2023 May; 23(1):162. PubMed ID: 37210478
[TBL] [Abstract] [Full Text] [Related]
19. Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic cancer.
Tsimberidou AM; Guenther K; Andersson BS; Mendrzyk R; Alpert A; Wagner C; Nowak A; Aslan K; Satelli A; Richter F; Kuttruff-Coqui S; Schoor O; Fritsche J; Coughlin Z; Mohamed AS; Sieger K; Norris B; Ort R; Beck J; Vo HH; Hoffgaard F; Ruh M; Backert L; Wistuba II; Fuhrmann D; Ibrahim NK; Morris VK; Kee BK; Halperin DM; Nogueras-Gonzalez GM; Kebriaei P; Shpall EJ; Vining D; Hwu P; Singh H; Reinhardt C; Britten CM; Hilf N; Weinschenk T; Maurer D; Walter S
Cancer Immunol Res; 2023 Jul; 11(7):925-945. PubMed ID: 37172100
[TBL] [Abstract] [Full Text] [Related]
20. Engineering an active immunotherapy for personalized cancer treatment and prevention of recurrence.
Wu K; Lyu F; Wu SY; Sharma S; Deshpande RP; Tyagi A; Zhao D; Xing F; Singh R; Watabe K
Sci Adv; 2023 Apr; 9(17):eade0625. PubMed ID: 37126558
[TBL] [Abstract] [Full Text] [Related]
[Next]
